Digital transformation at Novartis to improve customer engagement
The pharmaceutical industry was under siege, with regular price rollbacks and the powerful advance of generics frequently making news headlines. Many of the industry’s leading companies, including Novartis, were cutting their sales forces, while sales representatives who still had jobs felt increasingly disengaged. David Epstein, the head of Novartis’s Pharmaceuticals division, bucked the trend. He introduced a strategic initiative that aimed to fundamentally transform Novartis’ selling model. Epstein committed to an aspirational goal of equipping 80% of the company’s field forces worldwide with the latest iPad technology by the end of 2012, in just 15 months. A few months later, he set his teams an even more ambitious challenge: to equip 100% of the sales force by the end of 2013, which meant rolling out 25,000 new devices across the globe within a two-year period. Novartis was about to embark on a digital transformation journey, with the ultimate goal of providing the right drug to the right patient at the right time.
- Leading organizational transformation programmes
- New models of customer engagement in the pharmaceutical industry
- Harnessing the power of digital for strategic and operational change
Novartis, Healthcare, Pharmaceuticals
2011-2013
Cranfield University
Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]
Harvard Business School Publishing
60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]
NUCB Business School
1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
Research Information & Knowledge Hub for additional information on IMD publications
The Sandoz leadership team faced an important decision as it broke away from Novartis and became a public company. Should Sandoz retain the global geographical coverage it had had in its many years as part of Novartis? Or should it focus on fewer ...
This case series explores Sandoz's spin off from Novartis, which was finalized on 4 October 2023. Case A follows Richard Saynor's (CEO, Sandoz) ruminations as he builds the company strategy in preparation for the board's approval of Sandoz as a st...
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Case reference: IMD-2669 ©2025
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD Brain Circuits 4 September 2025
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD
Research Information & Knowledge Hub for additional information on IMD publications